Advanz Pharma is welcoming two executives. Steffen Wagner is joining as CEO, starting early 2022. He succeeds Graeme Duncan, who will step down from his role and become a special advisor to the Board.
Andreas Stickler, formerly with Merck Healthcare will become chief financial officer in January, succeeding Adeel Ahmad.
Wagner is currently a member of the executive management team at STADA Arzneimittel AG and has been responsible for the company's European Markets division. Wagner is a medical doctor by training, has previously held senior roles with Biogen and within the Novartis Group, and worked as a consultant at McKinsey and Bain. He brings extensive international pharma experience.
Duncan, who has been with Advanz since 2014, will continue working with the board as a special advisor.
[Read more: Retailers build out their specialty offerings]
Stickler was most recently CFO of Merck Healthcare, part of Merck KGaA, where he also served as global head of M&A and business development, driving major strategic acquisitions. He brings a wealth of global finance, healthcare and M&A expertise to the team. His predecessor, Adeel Ahmad, has been with the company since 2013 and has helped deliver major transformation projects and built a sustainable business from which to grow.
Other recent appointments include Susanna El-Armale as chief corporate development officer, following her prior role as chief corporate development officer of Theramex and succeeding former chief corporate development officer Guy Clark.
In January 2022, Chris Britten will join El-Armale's team as senior vice president for M&A, following his role as ead, M&A for Neuraxpharm.
[Read more: Currax welcomes new executives]
Anke Niedernberg recently joined as senior vice president and head of the transformation office. She brings a broad skillset to the leadership team, having spent time in private equity, consulting and running major change and growth projects for Sandoz for the last ten years.